Ultragenyx Pharmaceutical Inc.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $2.6M | $133.0K |
| Cost of Revenue | $1.0K | — |
| Gross Profit | $2.6M | — |
| Gross Margin | 100.0% | — |
| Operating Expenses | ||
| Research & Development | $231.6M | $183.2M |
| SG&A Expense | $99.9M | $64.9M |
| Operating Income | $-328.9M | $-248.0M |
| Operating Margin | -12,593.5% | -186,471.4% |
| Interest Expense | — | — |
| Pretax Income | $-318.3M | $-245.8M |
| Income Tax Expense | $-16.2M | $35.0K |
| Net Income | $-302.1M | $-245.9M |
| Net Margin | -11,567.3% | -184,867.7% |
| EPS (Basic) | $-7.12 | $-6.21 |
| EPS (Diluted) | $-7.12 | $-6.21 |
| Shares Outstanding (Basic) | 44.2M | 41.2M |
| Shares Outstanding (Diluted) | 44.2M | 41.2M |
| Dividends Per Share | — | — |